PMID- 31025425
OWN - NLM
STAT- MEDLINE
DCOM- 20200207
LR  - 20200207
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 33
IP  - 9
DP  - 2019 Sep
TI  - Immunological effects and potential mechanisms of action of autologous serum 
      therapy in chronic spontaneous urticaria.
PG  - 1747-1754
LID - 10.1111/jdv.15640 [doi]
AB  - BACKGROUND: Autoimmune processes are considered to play a major role in the 
      pathogenesis of chronic spontaneous urticaria (CSU). Very recently, interleukin 
      24 (IL-24) has been identified as an immunoglobulin E (IgE) autoantigen in CSU. 
      Some studies revealed that notably autologous serum skin test (ASST)-positive CSU 
      patients may benefit from autohemotherapy; however, the mechanisms of action 
      remain unknown. We aimed to investigate the immunological effects of autologous 
      serum injections in ASST-positive CSU patients. METHODS: Sixty-six ASST-positive 
      CSU patients were treated with weekly intramuscular autologous serum injections 
      for 8 weeks and followed up for 12 weeks. Urticaria activity score (UAS7) and 
      Dermatology Life Quality Index (DLQI) were assessed. The ASST was done at 
      baseline, week 9 and week 21. Serum samples (baseline, weeks 9, 13 and/or 21) 
      were analysed for the levels of IgE-anti-IL-24 and immunoglobulin G 
      (IgG)-anti-IL-24 via ELISA and their ability to release histamine in basophils 
      [basophil histamine release assay (BHRA)]. RESULTS: Autologous serum therapy 
      resulted in a substantial improvement in disease activity and quality of life 
      after 8 and 20 weeks. Twenty-eight percent and 34% of patients turned 
      ASST-negative in weeks 9 and 21, respectively, but there was no link between 
      their response to treatment and changes of ASST results. Also, no significant or 
      relevant changes in BHRA were observed. In contrast, autologous serum therapy 
      significantly decreased IgE-anti-IL-24 serum levels, but not IgG-anti-IL-24 serum 
      levels, in responders but not in non-responders. CONCLUSIONS: Our findings 
      suggest that the immunological effects of autologous serum therapy include a 
      reduction in IgE-anti-IL24 autoantibodies, which may contribute to the 
      pathogenesis of CSU.
CI  - (c) 2019 European Academy of Dermatology and Venereology.
FAU - Yu, L
AU  - Yu L
AD  - Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Buttgereit, T
AU  - Buttgereit T
AD  - Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Stahl Skov, P
AU  - Stahl Skov P
AD  - Odense Research Center of Anaphylaxis, Odense, Denmark.
FAU - Schmetzer, O
AU  - Schmetzer O
AD  - Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Scheffel, J
AU  - Scheffel J
AD  - Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Kocaturk, E
AU  - Kocaturk E
AD  - Department of Dermatology, Okmeydani Training and Research Hospital, Istanbul, 
      Turkey.
FAU - Zawar, V
AU  - Zawar V
AD  - Department of Dermatology, Godavari Foundation Medical College and Research 
      Center, Nashik, India.
FAU - Magerl, M
AU  - Magerl M
AD  - Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Maurer, M
AU  - Maurer M
AUID- ORCID: 0000-0002-4121-481X
AD  - Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, 
      Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190515
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Histamine Antagonists)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukins)
RN  - 0 (interleukin-24)
SB  - IM
MH  - Adult
MH  - Chronic Urticaria/*immunology/*therapy
MH  - Female
MH  - Germany
MH  - Histamine Antagonists/therapeutic use
MH  - Humans
MH  - Immunoglobulins/immunology
MH  - Immunotherapy/*methods
MH  - India
MH  - Injections, Intramuscular
MH  - Interleukins/immunology
MH  - Male
MH  - Quality of Life
MH  - Serum/*immunology
MH  - Skin Tests
MH  - Turkey
EDAT- 2019/04/27 06:00
MHDA- 2020/02/08 06:00
CRDT- 2019/04/27 06:00
PHST- 2019/01/15 00:00 [received]
PHST- 2019/04/01 00:00 [accepted]
PHST- 2019/04/27 06:00 [pubmed]
PHST- 2020/02/08 06:00 [medline]
PHST- 2019/04/27 06:00 [entrez]
AID - 10.1111/jdv.15640 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1747-1754. doi: 10.1111/jdv.15640. 
      Epub 2019 May 15.